Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

Mucosal Immunology

Volumn 1, Issue 3, 2008, Pages 208-218

  Kamijuku, H ^a   Nagata, Y ^b   Jiang, X ^b   Ichinohe, T ^e   Tashiro, T ^b   Mori, K ^b   Taniguchi, M ^b   Hase, K ^b   Ohno, H ^b   Shimaoka, T ^c   Yonehara, S ^d   Odagiri, T ^e   Tashiro, M ^e   Sata, T ^e   Hasegawa, H ^e   Seino, K I ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RIKEN Center for Integrative Medical Sciences   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; FLUORESCENT DYE; IMMUNOGLOBULIN A; INFLUENZA VACCINE; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL INTERACTION; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; DRUG POTENTIATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; MOUSE; NATURAL KILLER T CELL; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 42149161737     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2008.2     Document Type: Article

References (38)

1. Smidt, M.H., Stroink, H., Bruinenberg, J.F. & Peeters, M. Encephalopathy associated with influenza A. Eur. J. Paediatr. Neurol. 8, 257-260 (2004).
2. Check, E. Bird flu: On border patrol. Nature 442, 348-350 (2006).
3. Renegar, K.B. Influenza virus infections and immunity: A review of human and animal models. Lab. Anim. Sci. 42, 222-232 (1992).
4. Jackson, L.A. et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17, 1905-1909 (1999).
5. Pledra, P.A. et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110 662-672 (2002).
6. Tamura, S., Tanimoto, T. & Kurata, T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58, 195-207 (2005).
7. Asahi, Y. et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol. 168, 2930-2938 (2002).
8. + cytotoxic T lymphocytes. J. Infect. Dis. 183, 368-376 (2001).
9. Takada, A. et al. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21, 3212-3218 (2003).
10. Tumpey, T.M., Renshaw, M., Clements, J.D. & Katz, J.M Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75, 5141-5150 (2001).
11. Asahi-Ozaki, Y. et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J. Med. Virol. 74, 328-335 (2004).
12. Hasegawa, H. et al. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J. Med. Virol. 75, 130-136 (2005).
13. Tamura, S.I. & Kurata, T. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn. J. Infect. Dis. 53, 98-106 (2000).
14. van Ginkel, F.W., Jackson, R.J., Yuki, Y. & McGhee, J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778-4782 (2000).
15. Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004).
16. Kronenberg, M. Toward an understanding of NKT cell biology: Progress and paradoxes. Annu. Rev. Immunol. 23, 877-900 (2005).
17. Kawano, T. et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278, 1626-1629 (1997).
18. Taniguchi, M., Seino, K. & Nakayama, T. The NKT cell system: Bridging innate and acquired immunity. Nat. Immunol. 4, 1164-1165 (2003).
19. Ko, S.Y. et al. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175, 3309-3317 (2005).
20. Youn, H.J. et al. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25, 5189-5198 (2007).
21. O'Keeffe, J. et al. Diverse populations of T cells with NK cell receptors accumulate in the human intestine in health and in colorectal cancer. Eur. J. Immunol. 34, 2110-2119 (2004).
22. Harada, M. Down-regulation of invariant Valpha14 antigen receptor in NKT cells upon activation. Int. Immunol. 16, 241-247 (2004).
23. Jiang, X. et al. Cutting edge: Critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J. Immunol. 175 2051-2055 (2005).
24. Campos, R.A. et al. Cutaneous immunization rapidly activates liver invariant Valpha14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity. J. Exp. Med. 198, 1785-1796 (2003).
25. Galli, G. et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med. 197, 1051-1057 (2003).
26. Check, E. Avian flu special: Is this our best shot? Nature 435 404-406 (2005).
27. Benton, K.A. et al. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or γδ T cells. J. Immunol. 166, 7437-7445 (2001).
28. Giaccone, G. et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8, 3702-3709 (2002).
29. Ichinohe, T. et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79, 2910-2919 (2005).
30. Nicolson, C., Major, D., Wood, J.M. & Robertson, J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: An H5N1 candidate vaccine strain produced under a quality system. Vaccine 23, 2943-2952 (2005).
31. Cui, J. et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626 (1997).
32. Shimaoka, T. et al. Critical role for CXC chemokine ligand 16 (SR-PSOX) in Th1 response mediated by NKT cells. J. Immunol. 179, 8172-8179 (2007).
33. Tamura, S. et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 156 3892-3900 (1996).
34. Sever, J.L. Application of a microtechnique to viral serological investigations. J. Immunol. 88, 320-329 (1962).
35. Yetter, R.A., Lehrer, S., Ramphal, R. & Small, P.A. Jr. Outcome of influenza infection: Effect of site of initial infection and heterotypic immunity. Infect. Immun. 29, 654-662 (1980).
36. Tamura, S. et al. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J. Gen. Virol. 79, 291-299 (1998).
37. Kuhn, R., Rajewsky, K. & Muller, W. Generation and analysis of interleukin-4 deficient mice. Science 254, 707-710 (1991).
38. Tagawa, Y., Sekikawa, K. & Iwakura, Y. Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: Role for IFN-gamma in activating apoptosis of hepatocytes. J. Immunol. 159, 1418-1428 (1997).